Gene body methylation can alter gene expression and is a therapeutic target in cancer

Cancer Cell

Volumn 26, Issue 4, 2014, Pages 577-590

  Yang, Xiaojing ^a   Han, Han ^a   DeCarvalho, DanielD ^b,c   Lay, FidesD ^a   Jones, PeterA ^a,d   Liang, Gangning ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE 3B;

ARTICLE; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DOWN REGULATION; DRUG TARGETING; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; METABOLISM; NEOPLASM; ONCOGENE C MYC; PROMOTER REGION; CELL DIVISION; COLON TUMOR; GENETICS; PATHOLOGY;

CELL DIVISION; COLONIC NEOPLASMS; DNA METHYLATION; GENE EXPRESSION; HUMANS; PROMOTER REGIONS, GENETIC;

EID: 84907997839     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.07.028     Document Type: Article

References (62)

1. Andersson R., Enroth S., Rada-Iglesias A., Wadelius C., Komorowski J. Nucleosomes are well positioned in exons and carry characteristic histone modifications. Genome Res. 2009, 19:1732-1741.
2. Azad N., Zahnow C.A., Rudin C.M., Baylin S.B. The future of epigenetic therapy in solid tumours-lessons from the past. Nat. Rev. Clin. Oncol. 2013, 10:256-266.
3. Balch C., Nephew K.P. Epigenetic targeting therapies to overcome chemotherapy resistance. Adv. Exp. Med. Biol. 2013, 754:285-311.
4. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
5. Bender C.M., Gonzalgo M.L., Gonzales F.A., Nguyen C.T., Robertson K.D., Jones P.A. Roles of cell division and gene transcription in the methylation of CpG islands. Mol. Cell. Biol. 1999, 19:6690-6698.
6. Bernstein B.E., Birney E., Dunham I., Green E.D., Gunter C., Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74. ENCODE Project Consortium.
7. Butler E.B., Zhao Y., Muñoz-Pinedo C., Lu J., Tan M. Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. Cancer Res. 2013, 73:2709-2717.
8. Coleman-Derr D., Zilberman D. Deposition of histone variant H2A.Z within gene bodies regulates responsive genes. PLoS Genet. 2012, 8:e1002988.
9. Dang C.V. MYC on the path to cancer. Cell 2012, 149:22-35.
10. De Carvalho D.D., Sharma S., You J.S., Su S.F., Taberlay P.C., Kelly T.K., Yang X., Liang G., Jones P.A. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 2012, 21:655-667.
11. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
12. Edwards J.R., O'Donnell A.H., Rollins R.A., Peckham H.E., Lee C., Milekic M.H., Chanrion B., Fu Y., Su T., Hibshoosh H., et al. Chromatin and sequence features that define the fine and gross structure of genomic methylation patterns. Genome Res. 2010, 20:972-980.
13. Egger G., Jeong S., Escobar S.G., Cortez C.C., Li T.W., Saito Y., Yoo C.B., Jones P.A., Liang G. Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc. Natl. Acad. Sci. USA 2006, 103:14080-14085.
14. Gal-Yam E.N., Egger G., Iniguez L., Holster H., Einarsson S., Zhang X., Lin J.C., Liang G., Jones P.A., Tanay A. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc. Natl. Acad. Sci. USA 2008, 105:12979-12984.
15. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
16. Hellman A., Chess A. Gene body-specific methylation on the active X chromosome. Science 2007, 315:1141-1143.
17. Heyn H., Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat. Rev. Genet. 2012, 13:679-692.
18. Jones P.A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 2012, 13:484-492.
19. Jones P.A., Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980, 20:85-93.
20. Jones P.A., Liang G. Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet. 2009, 10:805-811.
21. Juergens R.A., Wrangle J., Vendetti F.P., Murphy S.C., Zhao M., Coleman B., Sebree R., Rodgers K., Hooker C.M., Franco N., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011, 1:598-607.
22. Kagey J.D., Kapoor-Vazirani P., McCabe M.T., Powell D.R., Vertino P.M. Long-term stability of demethylation after transient exposure to 5-aza-2'-deoxycytidine correlates with sustained RNA polymerase II occupancy. Mol. Cancer Res. 2010, 8:1048-1059.
23. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., Klimek V., Slack J., de Castro C., Ravandi F., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
24. Kelly T.K., De Carvalho D.D., Jones P.A. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 2010, 28:1069-1078.
25. Kelly T.K., Miranda T.B., Liang G., Berman B.P., Lin J.C., Tanay A., Jones P.A. H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes. Mol. Cell 2010, 39:901-911.
26. Kelly T.K., Liu Y., Lay F.D., Liang G., Berman B.P., Jones P.A. Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res. 2012, 22:2497-2506.
27. Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., Yamochi T., Urano T., Furukawa K., Kwabi-Addo B., et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008, 40:741-750.
28. Kulis M., Heath S., Bibikova M., Queirós A.C., Navarro A., Clot G., Martínez-Trillos A., Castellano G., Brun-Heath I., Pinyol M., et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 2012, 44:1236-1242.
29. Li Z., Gadue P., Chen K., Jiao Y., Tuteja G., Schug J., Li W., Kaestner K.H. Foxa2 and H2A.Z mediate nucleosome depletion during embryonic stem cell differentiation. Cell 2012, 151:1608-1616.
30. Li H., Chiappinelli K.B., Guzzetta A.A., Easwaran H., Yen R.W., Vatapalli R., Topper M.J., Luo J., Connolly R.M., Azad N.S., et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 2014, 5:587-598.
31. Liang G., Lin J.C., Wei V., Yoo C., Cheng J.C., Nguyen C.T., Weisenberger D.J., Egger G., Takai D., Gonzales F.A., Jones P.A. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc. Natl. Acad. Sci. USA 2004, 101:7357-7362.
32. Linhart H.G., Lin H., Yamada Y., Moran E., Steine E.J., Gokhale S., Lo G., Cantu E., Ehrich M., He T., et al. Dnmt3b promotes tumorigenesis invivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev. 2007, 21:3110-3122.
33. Lister R., Pelizzola M., Dowen R.H., Hawkins R.D., Hon G., Tonti-Filippini J., Nery J.R., Lee L., Ye Z., Ngo Q.M., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462:315-322.
34. Luco R.F., Allo M., Schor I.E., Kornblihtt A.R., Misteli T. Epigenetics in alternative pre-mRNA splicing. Cell 2011, 144:16-26.
35. Matei D., Fang F., Shen C., Schilder J., Arnold A., Zeng Y., Berry W.A., Huang T., Nephew K.P. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 2012, 72:2197-2205.
36. Maunakea A.K., Nagarajan R.P., Bilenky M., Ballinger T.J., D'Souza C., Fouse S.D., Johnson B.E., Hong C., Nielsen C., Zhao Y., et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010, 466:253-257.
37. Nag A., Savova V., Fung H.L., Miron A., Yuan G.C., Zhang K., Gimelbrant A.A. Chromatin signature of widespread monoallelic expression. Elife (Cambridge) 2013, 2:e01256.
38. Oki Y., Aoki E., Issa J.P. Decitabine-bedside to bench. Crit. Rev. Oncol. Hematol. 2007, 61:140-152.
39. Pandiyan K., You J.S., Yang X., Dai C., Zhou X.J., Baylin S.B., Jones P.A., Liang G. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res. 2013, 41:3973-3985.
40. Rhee I., Jair K.W., Yen R.W., Lengauer C., Herman J.G., Kinzler K.W., Vogelstein B., Baylin S.B., Schuebel K.E. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000, 404:1003-1007.
41. Rhee I., Bachman K.E., Park B.H., Jair K.W., Yen R.W., Schuebel K.E., Cui H., Feinberg A.P., Lengauer C., Kinzler K.W., et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416:552-556.
42. Salem C.E., Markl I.D., Bender C.M., Gonzales F.A., Jones P.A., Liang G. PAX6 methylation and ectopic expression in human tumor cells. Int. J. Cancer 2000, 87:179-185.
43. Sandoval J., Heyn H., Moran S., Serra-Musach J., Pujana M.A., Bibikova M., Esteller M. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 2011, 6:692-702.
44. Sharma S., De Carvalho D.D., Jeong S., Jones P.A., Liang G. Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet. 2011, 7:e1001286.
45. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., Stone R.M., Nelson D., Powell B.L., DeCastro C.M., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J.Clin. Oncol. 2002, 20:2429-2440.
46. Taylor S.M., Jones P.A. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 1979, 17:771-779.
47. Tilgner H., Nikolaou C., Althammer S., Sammeth M., Beato M., Valcárcel J., Guigó R. Nucleosome positioning as a determinant of exon recognition. Nat. Struct. Mol. Biol. 2009, 16:996-1001.
48. Tsai H.C., Li H., Van Neste L., Cai Y., Robert C., Rassool F.V., Shin J.J., Harbom K.M., Beaty R., Pappou E., et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012, 21:430-446.
49. Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., et al. Dynamic DNA methylation across diverse human cell lines and tissues. Genome Res. 2013, 23:555-567.
50. Venkatesh S., Smolle M., Li H., Gogol M.M., Saint M., Kumar S., Natarajan K., Workman J.L. Set2 methylation of histone H3 lysine 36 suppresses histone exchange on transcribed genes. Nature 2012, 489:452-455.
51. Wagner E.J., Carpenter P.B. Understanding the language of Lys36 methylation at histone H3. Nat. Rev. Mol. Cell Biol. 2012, 13:115-126.
52. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
53. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., Weisenberger D.J., Campan M., Young J., Jacobs I., Laird P.W. Epigenetic stem cell signature in cancer. Nat. Genet. 2007, 39:157-158.
54. Wilkerson M.D., Hayes D.N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010, 26:1572-1573.
55. Wolff E.M., Byun H.M., Han H.F., Sharma S., Nichols P.W., Siegmund K.D., Yang A.S., Jones P.A., Liang G. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 2010, 6:e1000917.
56. Wrangle J., Wang W., Koch A., Easwaran H., Mohammad H.P., Vendetti F., Vancriekinge W., Demeyer T., Du Z., Parsana P., et al. Alterations of immune response of non-small cell lung cancer with Azacytidine. Oncotarget 2013, 4:2067-2079.
57. Xiao S., Xie D., Cao X., Yu P., Xing X., Chen C.C., Musselman M., Xie M., West F.D., Lewin H.A., et al. Comparative epigenomic annotation of regulatory DNA. Cell 2012, 149:1381-1392.
58. Xie W., Schultz M.D., Lister R., Hou Z., Rajagopal N., Ray P., Whitaker J.W., Tian S., Hawkins R.D., Leung D., et al. Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell 2013, 153:1134-1148.
59. Yamazaki J., Issa J.P. Epigenetic aspects of MDS and its molecular targeted therapy. Int. J. Hematol. 2013, 97:175-182.
60. Yang X., Noushmehr H., Han H., Andreu-Vieyra C., Liang G., Jones P.A. Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. PLoS Genet. 2012, 8:e1002604.
61. Zemach A., McDaniel I.E., Silva P., Zilberman D. Genome-wide evolutionary analysis of eukaryotic DNA methylation. Science 2010, 328:916-919.
62. Zilberman D., Coleman-Derr D., Ballinger T., Henikoff S. Histone H2A.Z and DNA methylation are mutually antagonistic chromatin marks. Nature 2008, 456:125-129.